Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?

Marieke H. Otten*, Femke H. M. Prince, Rebecca ten Cate, Marion A. J. van Rossum, Marinka Twilt, Esther P. A. H. Hoppenreijs, Yvonne Koopman-Keemink, Arnold P. Oranje, Flora B. de Waard-van der Spek, Simone L. Gorter, Wineke Armbrust, Koert M. Dolman, Nico M. Wulffraat, Lisette W. A. van Suijlekom-Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objectives To evaluate the effectiveness of tumour necrosis factor (TNF) blockers in juvenile psoriatic arthritis (JPsA). Methods The study was a prospective ongoing multicentre, observational study of all Dutch juvenile idiopathic arthritis (JIA) patients using biologicals. The response of arthritis was assessed by American College of Rheumatology (ACR) paediatric response and Wallace inactive disease criteria. The response of psoriatic skin lesions was scored by a 5-point scale. Results Eighteen JPsA patients (72% female, median age onset 11.1 (range 3.3-14.6) years, 50% psoriatic skin lesions, 39% nail pitting, 22% dactylitis) were studied. The median follow-up time since starting anti-TNF alpha was 26 (range 3-62) months. Seventeen patients started on etanercept and one started on adalimumab. After 3 months of treatment 83% of the patients achieved ACR30 response, increasing to 100% after 15 months. Inactive disease reached in 67% after 39 months. There was no discontinuation because of inefficacy. Six patients discontinued treatment after a good clinical response. However, five patients flared and restarted treatment, all with a good response. During treatment four patients (two JPsA and two JIA patients with other subtypes) developed de novo psoriasis. In four of the nine patients the pre-existing psoriatic skin lesions improved. Conclusion Anti-TNF alpha therapy in JPsA seems effective in treating arthritis. However, in most patients the arthritis flared up after treatment discontinuation, emphasising the need to investigate optimal therapy duration. The psoriatic skin lesions did not respond well and four patients developed de novo psoriasis.
Original languageEnglish
Pages (from-to)337-340
JournalAnnals of the Rheumatic Diseases
Issue number2
Publication statusPublished - Feb 2011


Dive into the research topics of 'Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?'. Together they form a unique fingerprint.

Cite this